A district court ordered Boehringer Ingelheim Pharmaceuticals Inc. to cease making certain marketing claims that GlaxoSmithKline plc’s dry powder inhalers are not as effective for some patients. The ruling may encourage other companies to take disputes over comparative promotional campaigns to court since the US Food and Drug Administration has become more cautious about pursuing advertising violations.
Last year, GlaxoSmithKline filed suit against BI to halt its marketing campaign for BI’s Respimat slow mist inhaler (SMI), which...







